Fulcrum Therapeutics (FULC) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Fulcrum Therapeutics (FULC) over the past year, gaining 136.2% versus a loss of 67.3%. Over five years, GLSI leads with a -41.8% price change compared with -75.5% for FULC. Greenwich LifeSciences is the larger company by market cap ($282.6 million vs $281.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FULC | GLSI |
|---|---|---|
| Share price | $3.69 | $19.25 |
| Market cap | $281.85M | $282.56M |
| 1-day change | -0.54% | -2.73% |
| YTD return | -67.37% | -8.38% |
| 1-year return | -67.32% | +136.20% |
| 5-year return | -75.50% | -41.84% |
| EPS (TTM) | $-1.04 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-74.88M | $-19.36M |
| 52-week high | $15.74 | $34.10 |
| 52-week low | $2.83 | $7.78 |
| Distance from 52-week high | -76.56% | -43.55% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -0.54% | +198.70% |
| Average volume | 1.37M | 160.76K |
| Shares outstanding | 76.38M | 14.68M |
| Employees | 55 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed FULC by 203.5 percentage points over the past year.
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
FULC vs GLSI FAQ
Which is bigger, Fulcrum Therapeutics or Greenwich LifeSciences?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $282.56M compared with $281.85M for Fulcrum Therapeutics (FULC).
Which stock has performed better over the past year, FULC or GLSI?
GLSI returned +136.20% over the past 12 months, compared with -67.32% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Fulcrum Therapeutics and Greenwich LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.